KLAR: Klaria Pharma Holding AB (publ.) - Summary | Jitta

Klaria Pharma Holding AB (publ.)

SWE:KLAR

Price
kr0.61
Loss Chance
58.3%
0.79JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
84 / 107
539 / 619
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (16)
Recent Business Performance (11)
Financial Strength (30)
Return to Shareholders (13)
Competitive Advantage (26)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Revenue and EarningEarning loss detected in 2025
Operating MarginInconsistent
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
0.79
100.00%
2.00
103.99%
2.90
164.20%
Pharmaceuticals
5.68
191.55%
2.57
100.00%
2.75
100.00%
COMPANY DESCRIPTION
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. In addition, it is involved in commercialization and sale of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is based in Uppsala, Sweden.